Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.54 |
| ▸ | NR3C2 | P08235 | 14/20 | 0.54 |
| ▸ | PGR | P06401 | 12/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5007657 | 0.93 | NR3C1 (0.61) | NR3C1NR3C2PGR | |
| SCHEMBL4694320 | 0.92 | NR3C1 (0.55) | NR3C1NR3C2PGR | |
| SCHEMBL14037159 | 0.91 | NR3C1 (0.46) | NR3C1NR3C2PGR | |
| SCHEMBL5007683 | 0.90 | NR3C1 (0.61) | NR3C1NR3C2PGR | |
| SCHEMBL5007639 | 0.89 | NR3C1 (0.56) | NR3C1NR3C2PGR | |
| SCHEMBL5007642 | 0.88 | NR3C1 (0.56) | NR3C1NR3C2PGR | |
| SCHEMBL5009192 | 0.86 | NR3C1 (0.56) | NR3C1NR3C2PGR | |
| SCHEMBL5012938 | 0.86 | NR3C1 (0.54) | NR3C1NR3C2PGR | |
| SCHEMBL4695937 | 0.86 | NR3C1 (0.57) | NR3C1NR3C2PGR | |
| SCHEMBL5009721 | 0.86 | NR3C1 (0.57) | NR3C1NR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080292561-A1 | Pyrazolo-Pyrimidine Derivatives as Anti-Inflammatory Agents | GLAXO GROUP LIMITED | 2008-11-27 | — | — | US | claimed |
| US-20080292561-A1 | Pyrazolo-Pyrimidine Derivatives as Anti-Inflammatory Agents | GLAXO GROUP LIMITED | 2008-11-27 | — | — | US | disclosed |
| US-20080292561-A1 | Pyrazolo-Pyrimidine Derivatives as Anti-Inflammatory Agents | GLAXO GROUP LIMITED | 2008-11-27 | — | — | US | disclosed |
| EP-1945642-A1 | PYRAZOLO-PYRIMIDINE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | GLAXO GROUP LIMITED (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007054294-A1 | PYRAZOLO-PYRIMIDINE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | GLAXO GROUP LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292561-A1 | Pyrazolo-Pyrimidine Derivatives as Anti-Inflammatory Agents | NOD1, FPR3, FPR1 | NR3C1 141/4885NR3C2 268/4885PGR 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.